Who can take part?

• Documented diagnosis of IPF per the 2018 American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Society Clinical Practice Guideline (Raghu 2018).
• Chest high-resolution computed tomography (HRCT) performed within 12 months prior to first Screening Visit 
• FVC =45% of predicted normal at Screening Visits.
• Forced expiratory volume in 1 second (FEV1)/FVC =0.7 at Screening Visits.
• DLco =30% and =90% of predicted, corrected for hemoglobin at first Screening Visit.

Key exclusions:

• Abnormalities detected on electrocardiogram (ECG) of either rhythm or conduction that in the opinion of the Investigator are clinical significant.
• Emphysema present on =50% of the HRCT, or the extent of emphysema is greater than the extent of fibrosis, according to central review of the HRCT.
• Interstitial lung disease associated with known primary diseases 
• Participants who cannot meet protocol-specified baseline stability criteria.
• Acute IPF exacerbation within 3 months prior to screening.
• Receiving nintedanib in combination with pirfenidone
• Receiving systemic corticosteroids
• History of cigarette smoking or vaping within the previous 3 months.
• Female participant who is pregnant or breastfeeding.
• Previous exposure to study intervention or known allergy/sensitivity to study drug.
• Receiving an investigational treatment within 28 days of randomization.
• Inadequate IV access.

What is involved for me?

The study drug will be given to you by intravenous (IV) infusion every 2 weeks for 26 weeks with the last dose administered at Week 24.

This research study will include 2 study treatment groups:

• Axatilimab 0.3mg/kg; or
• Placebo

As part of this research study, you will have blood samples taken to assess your health throughout your participation.